Rituximab Archives - Medical Conferences

Novel first-line treatment option for mantle cell lymphoma

Presented By

Prof. Michael Wang, Anderson Cancer Center, TX, USA

Trial

Phase 3, SHINE

Conference

ASCO 2022

5 August, 2022 14:30

Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?

Presented By

Prof. Ulrich Specks, Mayo Clinic, MN, USA

Trial

Phase 3, ADVOCATE

Conference

ATS 2022

18 July, 2022 11:56

Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Expert

Dr Grzegorz Nowakowski, Mayo Clinic, Rochester, USA

Trial

Cohort study, RE-MIND2

Conference

ASH 2021

4 February, 2022 11:08

POLARIX: Novel regimen superior to R-CHOP in DLBCL

Presented By

Prof. Hervé Tilly, University of Rouen, France

Trial

Phase 3, POLARIX

Conference

ASH 2021

4 February, 2022 10:56

Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL

Expert

Dr Jennifer Woyach, Ohio State University, OH, USA

Trial

Phase 3, Alliance A041202

Conference

ASH 2021

3 February, 2022 23:22

Vaccine booster improves immune response in patients treated with rituximab

Presented By

Prof. Michael Bonelli, Medical University of Vienna, Austria

Conference

ACR 2021

14 January, 2022 11:07

Ultra-low dosing of rituximab in RA is a viable treatment option

Presented By

Mr Nathan den Broeder, Sint Maartenskliniek, the Netherlands

Trial

REDO

Conference

ACR 2021

14 January, 2022 10:58

Sequential rituximab after belimumab does not improve disease control in SLE

Presented By

Prof. Cynthia Aranow, Feinstein Institutes for Medical Research, NY, USA

Trial

Phase 3, BLISS-BELIEVE

Conference

ACR 2021

14 January, 2022 10:02

ASH 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASH 2021

4 January, 2022 08:00

Rituximab most effective initial MS therapy in Swedish real-world study

Presented By

Mr Peter Alping, Karolinska Institutet, Sweden

Trial

Phase 4, COMBAT-MS

Conference

ECTRIMS 2021

9 December, 2021 14:36

MS patients at risk of hampered immune response after vaccination

Presented By

Prof. Maria Pia Sormani, University of Genoa, Italy

Conference

ECTRIMS 2021

9 December, 2021 10:49

Anti-CD20 antibodies associated with worse COVID-19 outcomes

Presented By

Dr Steve Simpson-Yap, University of Melbourne, Australia

Conference

ECTRIMS 2021

9 December, 2021 10:41

Acquired TTP: new treatments and updated guidelines

Presented By

Dr María Mingot-Castellano, Hospital Universitario Virgen del Rocío, Spain

Trial

HERCULES; TITAN

Conference

EHA 2021

5 August, 2021 15:25

Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL

Presented By

Dr Mark-David Levin, Albert Schweitzer Hospital, the Netherlands

Trial

Phase 2, HOVON 139/GiVe

Conference

EHA 2021

5 August, 2021 13:38

MATRix with ASCT: best long-term survival for primary CNS lymphoma

Presented By

Dr Gerald Illerhaus, Klinikum der Landeshauptstadt Stuttgart, Germany

Trial

Phase 2, IELSG32

Conference

EHA 2021

5 August, 2021 12:05

Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Presented By

Dr Moshe Yair Levy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA

Conference

EHA 2021

5 August, 2021 11:55

JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA

Presented By

Dr Anja Strangfeld, German Rheumatism Research Centre Berlin, Germany

Conference

EULAR 2021

2 August, 2021 23:53

Rituximab or JAK inhibitors increase the risk of severe COVID-19

Presented By

Dr Jeffrey Sparks, Brigham and Women’s Hospital, MA, USA

Conference

EULAR 2021

2 August, 2021 23:36

Updates on COVID-19 vaccines in patients with rheumatic disease

Presented By

Dr Victoria Furer, Tel Aviv Sourasky Medical Center, Israel

Conference

EULAR 2021

2 August, 2021 22:44

JAK inhibitors and bDMARDs show comparable effectiveness

Presented By

Mr Andrei Barbulescu, Karolinska Institutet, Sweden

Conference

EULAR 2021

2 August, 2021 10:23

MS therapies influence COVID-19 severity

Conference

AAN 2021

16 June, 2021 11:42

Remission with rituximab in refractory generalised myasthenia gravis

Conference

AAN 2021

16 June, 2021 11:39

Do anti-CD20 DMTs cause worse COVID-19 outcomes in MS?

Presented By

Dr Steve Simpson-Yap, Melbourne School of Population and Global Health, Australia

Journal

Physician’s Weekly

Conference

MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting

15 April, 2021 16:27

Rheumatoid arthritis and interstitial lung disease: a deadly combination

Presented By

Prof. Joan Bathon, Columbia University, USA

Conference

ACR 2020

18 January, 2021 10:59

Poor disease control: a risk factor for severe COVID-19

Presented By

Prof. Rebecca Grainger, University of Otago, New Zealand

Trial

COVID-19 Global Rheumatology Alliance Registry

Conference

ACR 2020

18 January, 2021 10:57

Lupus nephritis: new therapies on the horizon in 2020

Presented By

Prof. Joan T. Merrill, Oklahoma Medical Research Foundation, USA

Conference

ACR 2020

18 January, 2021 10:54

Anti-CD20 DMTs associated with worse COVID-19 outcomes

Conference

MS Virtual 2020

25 November, 2020 17:09

Low-dose rituximab as effective as high-dose, but safer

Conference

MS Virtual 2020

25 November, 2020 16:57

Efficacy and safety of rituximab in refractory MG corroborated

Presented By

Dr A Dos Santos, University Hospital of Nantes, France

Conference

EAN 2020

10 September, 2020 14:24

Switching from natalizumab to moderate- versus high-efficacy DMT

Presented By

Dr Carrie M. Hersh, Cleveland Clinic Lerner College of Medicine, OH, USA

Conference

EAN 2020

10 September, 2020 12:17

Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis

Presented By

Dr Rona Smith, University of Cambridge, UK

Trial

RITAZAREM

Conference

ACR 2019

4 February, 2020 23:18

Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib

Presented By

Dr Evelyne Vinet, McGill University, Montreal, Canada

Conference

ACR 2019

4 February, 2020 23:12

Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration

Presented By

Prof. Costantino Pitzalis, Barts and The London School of Medicine and Dentistry, UK

Conference

ACR 2019

4 February, 2020 20:10

Rituximab beats mycophenolate mofetil in pemphigus vulgaris

Presented By

Prof. Pascal Joly, Rouen University Hospital, France

Trial

Phase 3, PEMPHIX, Ritux 3

Conference

EADV 2019

9 December, 2019 19:52

Risk of hypogammaglobulinemia and rituximab

Presented By

Dr Susanna Hallberg, Karolinska Institute, Sweden

Conference

ECTRIMS 2019

8 November, 2019 21:18

ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL

Presented By

Dr Paolo Ghia, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, ASCEND

Conference

EHA 2019

9 August, 2019 15:28

Rituximab/lenalidomide regimen shows clinical benefit in non-hodgkin lymphoma trials

Trial

MAGNIFY, AUGMENT

Conference

ASCO 2019

15 July, 2019 14:17

Promising results rituximab in systemic sclerosis, and systemic lupus erythematosus classification criteria

Presented By

Prof. Allanore, University of Paris Descartes University, France

Conference

EULAR 2018

24 August, 2018 22:49

Combining new drugs with different mechanisms

Trial

EXPLORER

Conference

ECCO 2018

28 May, 2018 23:31